Why Dynamics of Computer-Aided Drug Discovery Market Is Changing Drastically? What If History Is Any Guide?

Pune, New York, USA, November 17 2020 (Wiredrelease) Research Dive :According to a study conducted by Research Dive, the global computer-aided drug discovery market forecast size is expected to reach $4,878.5 billion by the end of 2026, registering 15.5% CAGR over the forecast period.

Computer-aided drug design utilizes computational methods to analyze, develop, and discover similar biologically active molecules. The ligand-based computer-aided drug discovery (LB-CADD) method includes the understanding of ligands which are known to interrelate with a targeted disease. These procedures use a set of referral structures that are collected from compounds known to interact with the target of interest and analyze their 2D or 3D structures.

The rising usage of pharmaco dynamics and pharmaco kinetic modelling in pre-clinical advancements is anticipated to drive the computer-aided drug discovery markets growth in the recent years. In addition, the rapid growth in the demand for latest technologies to decrease the cost

Read More

Drug Guardians Expands Website Providing More Information on Drug Side Effects

Drug_Gaurdians_Scales_of_Justice

Subscribe for Drug & Device Alerts to Receive Updated Information on FDA Warnings, Recalls, and Other Safety-Related Information
Subscribe for Drug & Device Alerts to Receive Updated Information on FDA Warnings, Recalls, and Other Safety-Related Information
Subscribe for Drug & Device Alerts to Receive Updated Information on FDA Warnings, Recalls, and Other Safety-Related Information

San Diego, CA, Nov. 06, 2020 (GLOBE NEWSWIRE) — Drug Guardians are pleased to announce that they have added new and latest information on drug side effects, FDA warnings, recalls, and other safety-related information to the public in general. The health care industry has been witnessing tremendous growth in prescription drugs and medical devices. Consumers on the other hand simply cannot keep up with the expanding number of treatment options and the potential side effects. This is one of the main concerns for the FDA, the US Food and Drug Administration. While prescription drugs and medical devices are highly profitable for the manufacturing companies, the FDA needs to protect the public from any

Read More

The Asia Pacific drug modelling software market is expected to reach US$ 2,401.22 million by 2027 from US$ 1,252.66 million in 2019

The market is estimated to grow at a CAGR of 8. 8% during 2020-2027. The drug modelling software market is growing primarily due to increasing adoption of in-silico modelling tools in drug discovery and rising economic burden of drug discovery in Asia Pacific.

New York, Nov. 03, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Drug Modelling Software Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By roduct Type ; Application, and Country” – https://www.reportlinker.com/p05978822/?utm_source=GNW
Additionally, growing adoption of artificial intelligence in drug discovery and strategic activities by market players are likely to fuel the growth of the drug modelling software market during the forecast period.

However, factors such as less adoption in emerging countries are likely to restrain the growth of the market.

Drug modelling has become an essential tool in the drug design process.Software-based drug discovery and development methods are playing

Read More

Alzheimer’s Drug Talks Heat Up; Brain-Computer Interface Goes for Jugular

Biogen’s controversial Alzheimer’s drug aducanumab — which goes before an FDA Advisory Committee panel this week — should not be approved because it failed to show efficacy, said Mayo Clinic’s David Knopman, MD, who was involved in one of the aducanumab trials, and others, in Alzheimer’s & Dementia.

Cleveland Clinic researchers did not agree, saying “lack of approval would be devastating not only to patients who will lose hope but advocates and the community at large.” (Alzheimer’s & Dementia)

A novel investigational PET tracer, 18F-PM-PBB3, captured abnormal tau protein deposits in Alzheimer’s disease and frontotemporal lobar degeneration disorders with high contrast. (Neuron)

Undiagnosed, untreated sleep disorders were tied to physician burnout. (JAMA Network Open)

No significant association was found between multiple sclerosis and vitiligo, a review concluded. (Nature Scientific Reports)

The Stentrode, an endovascular motor neuroprosthesis implanted via a jugular vein, helped two severely paralyzed patients with amyotrophic lateral

Read More

The Europe drug modelling software market is expected to reach US$ 3,215.94 million by 2027 from US$ 1,826.99 million in 2019

The market is estimated to grow at a CAGR of 7. 6% during 2020-2027. The drug modelling software market is growing primarily due to increasing adoption of in-silico modelling tools in drug discovery and rising economic burden of drug discovery in Europe.

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Europe Drug Modelling Software Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By roduct Type ; Application, and Country” – https://www.reportlinker.com/p05978847/?utm_source=GNW
Additionally, growing adoption of artificial intelligence in drug discovery and strategic activities by market players are likely to fuel the growth of the drug modelling software market during the forecast period.

However, factors such as lack of data standardization are likely to restrain the growth of the market.

Drug modelling has become an essential tool in the drug design process.Software-based drug discovery and development methods are playing a key role

Read More

Computer vision helps find binding sites in drug targets

Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5 minutes and find optimal spots for drug molecules to attach. The research was published in the Communications Biology journal.

Proteins, the molecules that control most biological processes, are typically the common targets for drugs. To produce a therapeutic effect, drugs should attach to proteins at specific sites called binding sites. The protein’s ability to bind to a drug is determined by the site’s amino acid sequence and spatial structure. Binding sites are real “hot spots” in pharmacology. The more binding sites are known, the more opportunities there are for creating more effective and safer drugs.

Skoltech CDISE assistant professor Petr Popov and PhD student Igor Kozlovskii developed

Read More